Xu F, Huang H, Feng J, Shen Q, Bao Y, Zhang D
J Neurol. 2024; 272(1):61.
PMID: 39680223
DOI: 10.1007/s00415-024-12856-6.
Yuan Y, Wang Y, Liu M, Luo H, Liu X, Li L
Front Neurol. 2024; 15:1404492.
PMID: 38751879
PMC: 11094647.
DOI: 10.3389/fneur.2024.1404492.
Vicente M, Addo-Osafo K, Vossel K
Front Neurol. 2024; 15:1277613.
PMID: 38390593
PMC: 10882721.
DOI: 10.3389/fneur.2024.1277613.
Chu Y, Hirst W, Federoff H, Harms A, Stoessl A, Kordower J
Brain. 2023; 147(2):444-457.
PMID: 38006313
PMC: 10834249.
DOI: 10.1093/brain/awad388.
Kulichikhin K, Malikova O, Zobnina A, Zalutskaya N, Rubel A
Life (Basel). 2023; 13(10).
PMID: 37895336
PMC: 10608209.
DOI: 10.3390/life13101954.
Tau: a biomarker of Huntington's disease.
Lepinay E, Cicchetti F
Mol Psychiatry. 2023; 28(10):4070-4083.
PMID: 37749233
DOI: 10.1038/s41380-023-02230-9.
Modeling Parkinson's disease in LRRK2 rodents.
Domenicale C, Magnabosco S, Morari M
Neuronal Signal. 2023; 7(3):NS20220040.
PMID: 37601008
PMC: 10432857.
DOI: 10.1042/NS20220040.
Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated.
Robinson J, Xie S, Baer D, Suh E, Van Deerlin V, Loh N
Brain. 2023; 146(6):2557-2569.
PMID: 36864661
PMC: 10232273.
DOI: 10.1093/brain/awad059.
High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson's disease.
Antoniou N, Prodromidou K, Kouroupi G, Boumpoureka I, Samiotaki M, Panayotou G
NPJ Parkinsons Dis. 2022; 8(1):15.
PMID: 35149677
PMC: 8837749.
DOI: 10.1038/s41531-022-00278-y.
Classification of diseases with accumulation of Tau protein.
Kovacs G, Ghetti B, Goedert M
Neuropathol Appl Neurobiol. 2022; 48(3):e12792.
PMID: 35064600
PMC: 9352145.
DOI: 10.1111/nan.12792.
The Neural Gut-Brain Axis of Pathological Protein Aggregation in Parkinson's Disease and Its Counterpart in Peroral Prion Infections.
Beekes M
Viruses. 2021; 13(7).
PMID: 34372600
PMC: 8310171.
DOI: 10.3390/v13071394.
Templated α-Synuclein Inclusion Formation Is Independent of Endogenous Tau.
Stoyka L, Mahoney C, Thrasher D, Russell D, Cook A, Harris A
eNeuro. 2021; 8(3).
PMID: 33972291
PMC: 8213444.
DOI: 10.1523/ENEURO.0458-20.2021.
Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease.
Thomzig A, Wagenfuhr K, Pinder P, Joncic M, Schulz-Schaeffer W, Beekes M
Acta Neuropathol. 2021; 141(6):861-879.
PMID: 33895878
PMC: 8068459.
DOI: 10.1007/s00401-021-02312-4.
Intracellular A53T Mutant α-Synuclein Impairs Adult Hippocampal Newborn Neuron Integration.
Regensburger M, Stemick J, Masliah E, Kohl Z, Winner B
Front Cell Dev Biol. 2020; 8:561963.
PMID: 33262984
PMC: 7686440.
DOI: 10.3389/fcell.2020.561963.
Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy.
Williams T, Sorrentino Z, Weinrich M, Giasson B, Chakrabarty P
Brain Commun. 2020; 2(2):fcaa090.
PMID: 33094280
PMC: 7567170.
DOI: 10.1093/braincomms/fcaa090.
Ablating Tau Reduces Hyperexcitability and Moderates Electroencephalographic Slowing in Transgenic Mice Expressing A53T Human α-Synuclein.
Peters S, Fahrenkopf A, Choquette J, Vermilyea S, Lee M, Vossel K
Front Neurol. 2020; 11:563.
PMID: 32636798
PMC: 7316964.
DOI: 10.3389/fneur.2020.00563.
The Accumulation of Tau in Postsynaptic Structures: A Common Feature in Multiple Neurodegenerative Diseases?.
Teravskis P, Ashe K, Liao D
Neuroscientist. 2020; 26(5-6):503-520.
PMID: 32389059
PMC: 8447404.
DOI: 10.1177/1073858420916696.
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities.
Visanji N, Lang A, Kovacs G
Transl Neurodegener. 2019; 8:28.
PMID: 31508228
PMC: 6727368.
DOI: 10.1186/s40035-019-0172-x.
Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression.
Sorrentino Z, Goodwin M, Riffe C, Dhillon J, Xia Y, Gorion K
Acta Neuropathol Commun. 2019; 7(1):142.
PMID: 31477175
PMC: 6718048.
DOI: 10.1186/s40478-019-0787-2.
Axonal pathology in hPSC-based models of Parkinson's disease results from loss of Nrf2 transcriptional activity at the Map1b gene locus.
Czaniecki C, Ryan T, Stykel M, Drolet J, Heide J, Hallam R
Proc Natl Acad Sci U S A. 2019; 116(28):14280-14289.
PMID: 31235589
PMC: 6628831.
DOI: 10.1073/pnas.1900576116.